Filing Analysis
Zentalis Pharmaceuticals, Inc. has entered into an underwriting agreement to conduct a public offering of 23,000,000 shares of common stock at $3.50 per share. The company expects to raise approximately $75.1 million in net proceeds to fund clinical trials and general corporate purposes.
🚩 Red Flags
- Significant dilution for existing shareholders due to the issuance of 23 million new shares.
- The offering price ($3.50) may be viewed as a signal regarding current market valuation or liquidity needs.
📋 Key Facts
- Offering size: 23,000,000 shares of common stock.
- Offering price: $3.50 per share.
- Underwriters include TD Securities (USA) LLC, Guggenheim Securities, LLC, and Oppenheimer & Co. Inc.
- Expected net proceeds: Approximately $75.1 million.
- Over-allotment option: Up to 3,450,000 additional shares.
- Expected closing date: August 17, 2026.
- Use of proceeds: Clinical trials, preclinical studies, regulatory filings, manufacturing, companion diagnostics, and working capital.
Zentalis Pharmaceuticals reported the results of its 2026 Annual Meeting of Stockholders held on June 16, 2026. The company confirmed the election of two Class III directors, the ratification of Ernst & Young LLP as its auditor, and the advisory approval of executive compensation.
📋 Key Facts
- Annual Meeting held on June 16, 2026.
- Quorum represented by 49,453,766 shares (approximately 69.47% of outstanding common stock).
- David Johnson and Jan Skvarka, Ph.D. were elected as Class III Directors.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2026.
- Executive compensation was approved on an advisory basis.
Zentalis Pharmaceuticals expanded its Board of Directors from six to seven members and appointed Shannon Campbell as a Class I director and member of the Compensation Committee, effective May 22, 2026.
📋 Key Facts
- Board size increased from 6 to 7 directors
- Shannon Campbell appointed as Class I director effective May 22, 2026
- Campbell appointed to the Compensation Committee
- Annual cash retainer: $45,000 for Board service and $7,500 for Compensation Committee service
- Initial RSU grant of 114,200 shares (0.16% of outstanding shares) granted May 26, 2026, vesting over 3 years
- Future annual RSU grants based on 0.08% of outstanding shares
Zentalis Pharmaceuticals announced positive Phase 1b clinical data for its drug candidate azenosertib in combination with paclitaxel for platinum-resistant ovarian cancer, to be presented at the 2026 ASCO Annual Meeting. The data showed promising efficacy, particularly in the 250 mg intermittent dose cohort, though safety findings included high-grade adverse events and one previously reported patient death.
🚩 Red Flags
- One Grade 5 event (death) due to sepsis was assessed as related to azenosertib by the investigator.
- High treatment discontinuation rate due to adverse events (32.6%).
- High rates of Grade >=3 hematological toxicities, including neutropenia (30.4%) and anemia (19.6%).
📋 Key Facts
- Data from Part 1 of the Phase 1b MUIR trial evaluating azenosertib in combination with paclitaxel in 46 patients with platinum-resistant ovarian cancer (PROC) will be presented at ASCO 2026.
- The overall response rate (ORR) across all cohorts (n=46) was 39.1%, and the clinical benefit rate (CBR) was 58.7%.
- In the optimal 250 mg intermittent dose cohort (n=12), the ORR was 50.0% and the median duration of response was 9.2 months.
- Safety data showed Grade >=3 treatment-related adverse events (TRAEs) of neutropenia (30.4%) and anemia (19.6%).
- 15 patients (32.6%) discontinued treatment due to adverse events, though approximately half were able to continue on azenosertib monotherapy.
Zentalis Pharmaceuticals announced its financial results for the first quarter ended March 31, 2026, and provided a business update. The company also released an updated corporate presentation for upcoming investor and analyst meetings.
📋 Key Facts
- Financial results for the quarter ended March 31, 2026, were announced on May 12, 2026.
- A new Corporate Presentation dated May 2026 was furnished as Exhibit 99.2.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
- The filing was signed by Julie Eastland, President and Chief Executive Officer.
Zentalis Pharmaceuticals announced the dosing of the first patient in its Phase 3 ASPENOVA clinical trial for azenosertib. The trial targets patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC) and is designed to support potential accelerated and full FDA approval.
📋 Key Facts
- The Phase 3 ASPENOVA trial is a randomized, confirmatory clinical trial.
- The trial expects to enroll approximately 420 patients.
- Azenosertib monotherapy (400mg QD 5:2) will be compared against investigator's choice of standard-of-care chemotherapy.
- The trial design incorporates U.S. FDA feedback regarding requirements for accelerated approval and conversion to full approval.
- The primary indication is Cyclin E1-positive platinum-resistant ovarian cancer (PROC).
Zentalis Pharmaceuticals disclosed scientific data presented at the 2026 AACR Annual Meeting regarding its lead candidate, azenosertib. The presentations cover preclinical activity in triple-negative breast cancer and real-world outcomes in Cyclin E1-positive ovarian cancer.
📋 Key Facts
- Presented data at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego (April 17-22, 2026).
- Exhibit 99.2 details preclinical models of WEE1 inhibitor azenosertib in Triple-Negative Breast Cancer (TNBC).
- Exhibit 99.3 analyzes real-world treatment patterns and outcomes for patients with Cyclin E1-positive Ovarian Cancer.
- The disclosures were made under Item 7.01 Regulation FD and are not deemed 'filed' for liability purposes.
Zentalis Pharmaceuticals announced the selection of 400mg QD 5:2 as the optimal monotherapy dose for azenosertib in ovarian cancer following positive interim Phase 2 data. The company plans to initiate a Phase 3 confirmatory trial in Q2 2026 and expects a topline readout for the Phase 2 trial by year-end 2026.
📋 Key Facts
- Selected 400mg QD 5:2 as the optimal monotherapy dose for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer (PROC).
- The 400mg dose showed a 'meaningful and clearly differentiated response rate' over the 300mg dose with comparable safety.
- Initiation of the confirmatory ASPENOVA Phase 3 clinical trial is expected in Q2 2026.
- Expanded the DENALI Phase 2 trial to include Part 2c, broadening the study to patients previously treated with taxane-containing regimens.
- Company projects existing cash and marketable securities will fund operations into late 2027.
- Topline readout for the registration-intended DENALI Part 2 trial is expected by year-end 2026.
Zentalis Pharmaceuticals announced its full-year 2025 financial results and provided business updates on March 26, 2026. The information was disclosed via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Financial results reported for the fiscal year ended December 31, 2025
- Filing includes business updates alongside financial data
- Reported under Item 2.02 (Results of Operations and Financial Condition)
- Press release issued and furnished on March 26, 2026
Zentalis Pharmaceuticals provided a corporate update highlighting clinical milestones for its lead program, azenosertib, and confirmed a cash runway extending into late 2027. The company is focusing on Phase 3 trial design alignment with the FDA and upcoming data readouts in 2026.
🚩 Red Flags
- Company acknowledges it has incurred and expects to continue to incur significant losses.
- Heavy dependence on the success of a single lead candidate, azenosertib.
📋 Key Facts
- Completed enrollment in DENALI Part 2a clinical trial for azenosertib.
- Aligned with the FDA on the design of the ASPENOVA Phase 3 confirmatory trial.
- As of Sept 30, 2025, the company held $280.7 million in cash, cash equivalents, and marketable securities.
- Cash runway is estimated to extend into late 2027 following a strategic restructuring.
- DENALI Part 2 topline readout expected by year-end 2026.
Zentalis Pharmaceuticals announced the resignation of Board member Karan Takhar and a simultaneous stock repurchase agreement with Matrix Capital Master Fund, LP. The company is repurchasing 7.5 million shares at $1.33 per share to facilitate the wind-down of Matrix's funds.
🚩 Red Flags
- Related-party transaction: The company is repurchasing a significant block of shares (7.5M) from an entity associated with a departing director.
- Potential liquidity drain: While management states it won't impact cash runway into late 2027, the $9.975M outflow is notable for a micro-cap/mid-cap biotech.
📋 Key Facts
- Karan Takhar resigned from the Board of Directors and all committees effective December 15, 2025.
- The Company is repurchasing 7,500,000 shares of common stock from Matrix Capital Master Fund, LP.
- Repurchase price is $1.33 per share (a discount to the Dec 12 closing price of $1.40).
- Total repurchase value is approximately $9.975 million.
- The transaction facilitates the wind-down of Matrix Capital Management Company L.P.'s family of funds.
- Board size reduced from seven to six directors.
Zentalis Pharmaceuticals announced its financial results for the quarter ended September 30, 2025. The filing includes a press release and an updated corporate presentation.
📋 Key Facts
- Reported financial results for the quarter ended September 30, 2025.
- Released an updated Corporate Presentation (Exhibit 99.2) to be used in investor conferences starting November 10, 2025.
- The filing is a standard quarterly earnings announcement under Item 2.02 and Regulation FD disclosure under Item 7.01.
Zentalis Pharmaceuticals announced the resignation of its Chief Legal Officer and Corporate Secretary, Andrea Paul, effective September 18, 2025. She will be succeeded by James B. Bucher, a seasoned life sciences legal executive.
🚩 Red Flags
- None identified; departure is for a standard career advancement (law firm partnership).
📋 Key Facts
- Andrea Paul to resign as CLO and Corporate Secretary on September 18, 2025.
- Ms. Paul is leaving to join the partnership of a large, international law firm.
- James B. Bucher appointed as new Chief Legal Officer and Corporate Secretary, effective September 18, 2025.
- Ms. Paul will remain a non-executive employee through October 1, 2025, for transition purposes.
- The company expects to enter into a release agreement including her 2025 target annual bonus and continued equity vesting during the transition.
Zentalis Pharmaceuticals announced its financial results for the quarter ended June 30, 2025. The filing includes a press release and an updated corporate presentation to be used in investor meetings.
📋 Key Facts
- Reported financial results for the quarter ending June 30, 2025.
- Issued a new Corporate Presentation (Exhibit 99.2) effective August 6, 2025.
- The filing is primarily to furnish quarterly earnings data and investor presentation materials.
Zentalis Pharmaceuticals, Inc. held its 2025 Annual Meeting of Stockholders on June 17, 2025. The meeting resulted in the election of three Class II directors and the ratification of Ernst & Young LLP as the independent auditor.
🚩 Red Flags
- High number of 'Broker Non-Votes' across director elections and advisory compensation votes suggests significant portion of shares were not instructed on these specific items by brokers.
📋 Key Facts
- Annual Meeting held on June 17, 2025.
- Quorum reached with 58,212,103 shares present (approx. 80.9% of outstanding common stock).
- Scott Myers, Karan Takhar, and Luke Walker, M.D. were elected to the Board as Class II directors.
- Ernst & Young LLP was ratified as independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Say-on-pay (advisory compensation of named executive officers) was approved.
Zentalis Pharmaceuticals disclosed information presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting regarding Phase 1 dose escalation results for Azenosertib in combination with Encorafenib and Cetuximab.
📋 Key Facts
- Presented data at the ASCO Annual Meeting on May 31, 2025.
- Clinical focus: Phase 1 Dose Escalation Results of WEE Inhibitor Azenosertib + Encorafenib + Cetuximab.
- Target patient population: Previously treated BRAFV600E Mutant Metastatic Colorectal Cancer.
Zentalis Pharmaceuticals, Inc. announced its upcoming participation in several investor conferences scheduled for May and June 2025. The filing serves as a routine disclosure of non-public material information via Regulation FD.
📋 Key Facts
- Company will present at H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025.
- Company will participate in TD Cowen’s 6th Annual Oncology Innovation Summit on May 27, 2025.
- Company will present at Jefferies Healthcare Conference on June 4, 2025.
Zentalis Pharmaceuticals announced its financial results for the quarter ended March 31, 2025. The filing serves as a formal announcement of quarterly earnings and business updates.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2025
- Announcement date: May 14, 2025
- The company provided financial results and business updates via a press release (Exhibit 99.1)
- Information under Item 2.02 is furnished but not filed for purposes of Section 18 liability.
Zentalis Pharmaceuticals filed an 8-K to furnish clinical data posters presented at the 2025 AACR Annual Meeting. The filing includes information regarding their WEE1 inhibitor, azenosertib, across various cancer models and patient responses.
📋 Key Facts
- The company is presenting data at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago (April 25-30, 2025).
- Exhibits include posters on azenosertib's efficacy in TP53-mutated cancer cells and HGSOC patients.
- Data covers azenosertib as a potent WEE1 kinase inhibitor with broad antitumor activity.
- Research includes synergistic anti-tumor activity of azenosertib with encorafenib + cetuximab in BRAF V600E models.
Zentalis Pharmaceuticals announced its financial results for the fiscal year ended December 31, 2024. The filing serves as a formal announcement of annual earnings and business updates.
📋 Key Facts
- Reported date: March 26, 2025
- Reporting period: Fiscal year ended December 31, 2024
- The company provided business updates alongside financial results via Exhibit 99.1.
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Zentalis Pharmaceuticals issued an 8-K to furnish a press release and a presentation regarding the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting. The filing is primarily for regulatory compliance under Regulation FD.
📋 Key Facts
- Company presented at the SGO 2025 Annual Meeting in Seattle, WA (March 14–17, 2025).
- The filing includes a press release dated March 15, 2025 (Exhibit 99.1).
- The filing includes the 2025 SGO Annual Meeting Presentation (Exhibit 99.2).
- Information is furnished under Item 7.01 and is not considered 'filed' for purposes of Section 18 liability.
Zentalis Pharmaceuticals announced a strategic pivot to focus its WEE1 inhibitor, azenosertib, on Cyclin E1-positive platinum-resistant ovarian cancer (PROC). The company also released clinical data from several studies, including Phase 1 and Phase 2 trials.
🚩 Red Flags
- Discontinuation of azenosertib/niraparib combination development.
- Decision not to advance into dose expansion for the Pfizer-collaborated BRAF V600E mutant colorectal cancer study (ZN-c3-016) due to resource prioritization.
📋 Key Facts
- Azenosertib development will focus on Cyclin E1-positive PROC patients using a proprietary IHC assay.
- The DENALI Part 2 study is designed for seamless enrollment across Parts 2a and 2b, with topline data expected by year end 2026.
- Successful DENALI Part 2 results could support accelerated FDA approval.
- ZN-c3-001 (Phase 1) showed an ORR of 34.8% in Cyclin E1-positive PROC patients at intermittent dosing schedules.
- MAMMOTH study monotherapy arm showed an ORR of 31.3% for Cyclin E1-positive patients at the 400mg dose level.
- The company is discontinuing the azenosertib + niraparib combination due to lack of efficacious exposures.
Zentalis Pharmaceuticals has announced a strategic restructuring involving a ~40% workforce reduction to extend its cash runway. The move is intended to support the late-stage development of its WEE1 inhibitor, azenosertib, through anticipated data readouts in late 2026.
🚩 Red Flags
- Significant workforce reduction (40%) indicates aggressive cost-cutting/liquidity management.
- Heavy reliance on a single lead product candidate (azenosertib) for future viability.
- Implicit need to extend cash runway suggests previous burn rates were unsustainable relative to upcoming clinical milestones.
📋 Key Facts
- Workforce reduction of approximately 40% expected to be completed by Q2 2025.
- One-time restructuring costs estimated at $7.0–$8.0 million in Q1 2025.
- Company expects current cash, equivalents, and marketable securities to fund operations into late 2027.
- Focus is on the development of azenosertib (WEE1 inhibitor) and the DENALI Part 2 study readout expected by end of 2026.
Zentalis Pharmaceuticals, Inc. filed an amendment to its previous 8-K to disclose the appointment of Scott Myers to the Compensation Committee and his associated annual retainer.
📋 Key Facts
- Amendment (Form 8-K/A) to a previously filed report from November 13, 2024.
- Scott Myers has been appointed as a member of the Compensation Committee effective December 17, 2024.
- Mr. Myers will receive an annual retainer of $7,500 for his service on this committee.
Zentalis Pharmaceuticals announced a major leadership transition effective November 13, 2024, involving the departure of its CEO and President. The company has appointed Julie Eastland as the new CEO and President to succeed Dr. Kimberly Blackwell.
🚩 Red Flags
- Simultaneous departure of CEO, President, and Interim CFO creates significant management instability.
- High executive turnover in a single filing (CEO, President/Interim CFO, and Director changes).
- Significant severance obligations for departing executives (Dr. Blackwell).
📋 Key Facts
- Dr. Kimberly Blackwell resigned as CEO and from the Board, effective Nov 13, 2024; she will serve as a strategic advisor through Nov 15, 2025.
- Julie Eastland appointed as new CEO, President, and Class I director, effective Nov 13, 2024.
- Cam Gallagher resigned as President and Interim CFO, effective Nov 13, 2024; he will serve as an advisor.
- Vincent Vultaggio (SVP, Finance and Principal Accounting Officer) appointed as interim Principal Financial Officer, effective Nov 13, 2024.
- Julie Eastland's compensation includes a $700,000 base salary, 60% target bonus, and a $250,000 sign-on bonus.
- Dr. Blackwell received severance including 18 months of base salary and 1.25x her 2024 target bonus.
Zentalis Pharmaceuticals announced that the FDA has lifted a partial clinical hold on certain studies of its drug candidate, azenosertib. The company is now cleared to resume enrollment in all ongoing azenosertib clinical studies without changes to the development plan.
🚩 Red Flags
- None identified in this filing; the lifting of a hold is a positive regulatory event.
📋 Key Facts
- FDA has lifted the partial clinical hold placed on June 18, 2024, regarding azenosertib clinical studies.
- The company is cleared to resume enrollment in all ongoing azenosertib clinical studies.
- No changes to the clinical development plan are required by the FDA.
Zentalis Pharmaceuticals announced its financial results for the second quarter ended June 30, 2024, and provided various business updates via a press release.
📋 Key Facts
- Reported date: August 9, 2024
- Period covered: Quarter ended June 30, 2024
- The filing includes results of operations and financial condition under Item 2.02.
- Company provided business updates alongside the earnings release.
Zentalis Pharmaceuticals held its 2024 Annual Meeting of Stockholders on June 21, 2024. The meeting resulted in the election of two Class I directors and the ratification of Ernst & Young LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 21, 2024.
- Quorum represented 66,107,445 shares, approximately 93.09% of outstanding common stock.
- Kimberly Blackwell, M.D. and Enoch Kariuki, Pharm.D. were elected to the Board as Class I directors.
- Ernst & Young LLP was ratified as independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- Say-on-pay (advisory vote on executive compensation) was approved.
Zentalis Pharmaceuticals filed an 8-K to provide notice that it will use its updated Corporate Presentation (Exhibit 99.1) for investor conferences and meetings starting June 3, 2024.
📋 Key Facts
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
- Company plans to present information from the Corporate Presentation dated June 2024 at upcoming investor conferences and meetings.
- The presentation is furnished but not 'filed' for purposes of Section 18 liability.
Zentalis Pharmaceuticals, Inc. announced the appointment of Luke Walker, M.D., to its Board of Directors and Audit Committee. This expansion increases the size of the Board from six to seven members.
📋 Key Facts
- Effective date: May 24, 2024
- New Director: Luke Walker, M.D. (Class II director)
- Board size increased from six to seven directors
- Dr. Walker appointed to the Audit Committee
- Annual retainer for Board service: $45,000
- Additional annual retainer for Audit Committee service: $10,000
- Initial RSU grant: 72,481 shares (based on a $850,000 value) vesting over three years
- Annual equity grant of RSUs valued at $425,000 starting after six months of service
Zentalis Pharmaceuticals announced its financial results for the quarter ended March 31, 2024, and provided various business updates via a press release.
📋 Key Facts
- Report date: May 7, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing includes results of operations and financial condition (Item 2.02).
- Business updates were provided alongside the quarterly earnings.
Zentalis Pharmaceuticals announced the immediate resignation of its CFO, Treasurer, and principal financial/accounting officers on April 5, 2024. The company has appointed interim leadership to fill these critical roles while conducting a search for a permanent replacement.
🚩 Red Flags
- Immediate departure of the CFO and principal accounting officer creates temporary leadership instability in financial reporting functions.
- The suddenness of the resignation (effective immediately) can sometimes signal internal friction or disagreements, though not explicitly stated here.
📋 Key Facts
- Melissa Epperly resigned as CFO, Treasurer, principal financial officer, and principal accounting officer effective April 5, 2024.
- Cam Gallagher (Company President) appointed as interim CFO, Treasurer, and principal financial officer.
- Vincent Vultaggio (VP, Finance) appointed as interim principal accounting officer.
- Kyle Rasbach (Chief Business Officer) will oversee Investor Relations on an interim basis.
- Ms. Epperly is eligible for severance subject to a release agreement.
Zentalis Pharmaceuticals filed an 8-K to announce that it will use its updated Corporate Presentation (Exhibit 99.1) for investor conferences and meetings starting April 9, 2024.
📋 Key Facts
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
- Company plans to present the information in Exhibit 99.1 at upcoming conferences and analyst meetings.
- The Corporate Presentation dated April 2024 is furnished but not 'filed' for purposes of Section 18 liability.
Zentalis Pharmaceuticals announced its full-year 2023 financial results and provided a business update via a press release. The filing serves as the formal mechanism to furnish these earnings results under Item 2.02.
📋 Key Facts
- Announced financial results for the fiscal year ended December 31, 2023.
- Provided commentary on certain business updates.
- Filed on February 27, 2024.
Zentalis Pharmaceuticals, Inc. has amended its Bylaws to align with SEC universal proxy rules and streamline stockholder nomination procedures. The changes include clarifying solicitation requirements under Rule 14a-19 and prohibiting the submission of more director nominees than seats available.
📋 Key Facts
- Board approved and adopted Amended and Restated Bylaws on February 12, 2024.
- Amendments address SEC universal proxy rules regarding proxy solicitation for director nominees.
- New bylaws clarify compliance requirements under Rule 14a-19 of the Exchange Act.
- Procedures for stockholder nominations and proposals have been streamlined/enhanced.
- The company prohibits proposing stockholders from submitting more director nominees than there are vacancies up for election.
Zentalis Pharmaceuticals announced a leadership transition where Dr. Diana Hausman has succeeded Dr. Carrie Brownstein as Chief Medical Officer, effective January 19, 2024. This change resulted in the company falling out of compliance with Nasdaq's Audit Committee independence requirements.
🚩 Red Flags
- Delisting risk: Received formal notification from Nasdaq regarding non-compliance with Audit Committee independence rules.
- Governance disruption: The simultaneous resignation of an officer from the Board and committees creates a temporary governance gap.
📋 Key Facts
- Dr. Diana Hausman appointed as Chief Medical Officer effective Jan 19, 2024.
- Dr. Carrie Brownstein stepped down as CMO for personal reasons; will serve as a consultant for two months.
- Severance package for Dr. Brownstein includes 10 months' base salary, target bonus for 2023, prorated 2024 bonus, and 12 months of COBRA premiums.
- Dr. Hausman resigned from the Board, Audit Committee, and Nominating/Corporate Governance Committee to take the CMO role.
- Nasdaq notified the company on Jan 24, 2024, regarding non-compliance with Rule 5605(c)(2) due to insufficient independent directors on the Audit Committee.
- The company has 180 days (until July 17, 2024) to appoint a third independent director to regain compliance.
Zentalis Pharmaceuticals has entered into an exclusive, worldwide licensing agreement with Immunome, Inc. for its ROR1 ADC (ZPC-21) and proprietary ADC platform technology. The deal includes significant upfront funding and substantial milestone potential.
📋 Key Facts
- Exclusive, worldwide license granted to Immunome, Inc.
- Licensed assets include ZPC-21 (preclinical ROR1 antibody-drug conjugate) and the proprietary ADC platform technology.
- Upfront payment of $35 million consisting of cash and Immunome common stock.
- Potential milestone payments totaling up to $275 million for ZPC-21 and other platform-derived products.
- Agreement includes mid-to-high single-digit royalties.